According to AstraZeneca's latest financial reports the company has $5.81 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $6.40 B | 0.11% |
2021-12-31 | $6.39 B | -19.94% |
2020-12-31 | $7.99 B | 28.53% |
2019-12-31 | $6.21 B | 9.47% |
2018-12-31 | $5.68 B | 24.73% |
2017-12-31 | $4.55 B | -22.84% |
2016-12-31 | $5.90 B | -13.88% |
2015-12-31 | $6.85 B | -4.22% |
2014-12-31 | $7.15 B | -28.54% |
2013-12-31 | $10.01 B | 17.47% |
2012-12-31 | $8.52 B | -27.88% |
2011-12-31 | $11.81 B | -5.82% |
2010-12-31 | $12.55 B | 9.84% |
2009-12-31 | $11.42 B | 160.21% |
2008-12-31 | $4.39 B | -27.35% |
2007-12-31 | $6.04 B | -22.11% |
2006-12-31 | $7.76 B | 17.52% |
2005-12-31 | $6.60 B | 25.41% |
2004-12-31 | $5.26 B | 33.26% |
2003-12-31 | $3.95 B | -15.76% |
2002-12-31 | $4.69 B | -14.17% |
2001-12-31 | $5.46 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | $24.61 B | 323.49% | ๐บ๐ธ USA |
![]() Novartis NVS | $11.17 B | 92.26% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | $19.97 B | 243.63% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | $9.53 B | 64.01% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | $2.82 B | -51.32% | ๐บ๐ธ USA |
![]() Sanofi SNY | $8.68 B | 49.46% | ๐ซ๐ท France |
![]() Biogen BIIB | $6.07 B | 4.58% | ๐บ๐ธ USA |
![]() Merck MRK | $10.38 B | 78.72% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | $8.37 B | 44.05% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | $8.20 B | 41.17% | ๐ฌ๐ง UK |